<p>西氏醫藥服務（NYSE:WST - 獲取免費報告）在週三發佈的研究報告中被 Zacks Research 的股票研究人員從 “持有” 評級上調至 “強力買入” 評級，Zacks.com 報道。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他分析師也對該股票發佈了研究報告。Evercore 在 4 月 24 日的研究報告中重申了對西氏醫藥服務股票的 “跑贏大盤” 評級。瑞銀集團在 2 月 13 日的研究報告中重申了 “買入” 評級，並設定了 340.00 美元的目標價。德意志銀行在 2 月 13 日的研究報告中重申了 “買入” 評級，並設定了 315.00 美元的目標價。花旗集團在 4 月 24 日的研究報告中重申了對西氏醫藥服務的 “買入” 評級。最後，巴克萊在 4 月 27 日的研究報告中將西氏醫藥服務的目標價從 275.00 美元上調至 310.00 美元，並給予該公司 “持平” 評級。兩位研究分析師對該股票給予了強力買入評級，七位給予了買入評級，三位給予了持有評級。根據 MarketBeat.com 的數據，西氏醫藥服務目前的平均評級為 “適度買入”，共識目標價為 322.89 美元。</p>
<p><strong>閲讀我們關於西氏醫藥服務的最新報告</strong></p>
<h2>西氏醫藥服務股票下跌 0.7%</h2>
<ul>
<li>什麼因素將推動標準普爾 500 指數今年的表現？</li>
</ul>
<p>WST 股票在週三開盤價為 300.13 美元。該公司的市值為 212 億美元，市盈率為 40.12，市盈增長比率為 2.53，貝塔值為 1.17。公司的債務與股本比率為 0.07，速動比率為 2.04，流動比率為 2.71。該公司的 50 日移動平均價格為 267.64 美元，200 日移動平均價格為 265.17 美元。西氏醫藥服務的年內最低價為 202.79 美元，年內最高價為 330.88 美元。</p>
<p>西氏醫藥服務（NYSE:WST - 獲取免費報告）在 4 月 23 日星期四發佈了季度財報。這家醫療器械供應商報告季度每股收益為 2.13 美元，超出市場共識預期的 1.68 美元，超出幅度為 0.45 美元。該公司季度收入為 8.449 億美元，而分析師預期為 7.7968 億美元。西氏醫藥服務的淨利潤率為 16.85%，股本回報率為 19.03%。該公司季度收入同比增長 21.0%。在去年同期，該公司每股收益為 1.45 美元。西氏醫藥服務已將其 2026 財年的指導目標設定為每股收益 8.400-8.750 美元，2026 年第二季度的指導目標設定為每股收益 2.050-2.120 美元。平均而言，股票研究分析師預計西氏醫藥服務今年將發佈每股收益 8.61 美元。</p>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>西氏醫藥服務宣佈其董事會於 2 月 17 日啓動了一項股票回購計劃，允許公司回購 10 億美元的流通股。該回購授權允許這家醫療器械供應商通過公開市場購買最多 5.6% 的股份。股票回購計劃通常表明公司的領導層認為其股票被低估。</p>
<h2>內部買賣</h2>
<p>在其他西氏醫藥服務的新聞中，首席會計官 Chad Winters 在 4 月 27 日星期一出售了 896 股公司的股票。股票以平均價格 300.67 美元出售，總價值為 269,400.32 美元。出售後，首席會計官持有 1,523 股公司的股票，價值為 457,920.41 美元。此次交易使其持股減少了 37.04%。該出售在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，副總裁 Annette F. Favorite 在 4 月 27 日星期一出售了 2,817 股公司的股票。股票以平均價格 305.20 美元出售，總價值為 859,748.40 美元。出售完成後，副總裁直接持有公司 16,828 股，價值約為 5,135,905.60 美元。此次交易使其持股減少了 14.34%。該出售的 SEC 文件提供了更多信息。0.60% 的股票由內部人士持有。</p>
<h2>西氏醫藥服務的機構交易</h2>
<p>大型投資者最近調整了對該股票的持有。Elyxium Wealth LLC 在第四季度購買了西氏醫藥服務的新股份，價值 25,000 美元。Bayban 在第四季度購買了西氏醫藥服務的新股份，價值 27,000 美元。Private Trust Co. NA 在第四季度將其在西氏醫藥服務的持股增加了 156.4%。Private Trust Co. NA 現在擁有 100 股這家醫療器械供應商的股票，價值 28,000 美元，此前在此期間又購買了 61 股。DV Equities LLC 在第四季度購買了西氏醫藥服務的新股份，價值 28,000 美元。最後，Cornerstone Planning Group LLC 在第一季度將其在西氏醫藥服務的持股增加了 90.9%。Cornerstone Planning Group LLC 現在擁有 105 股這家醫療器械供應商的股票，價值 26,000 美元，此前在此期間又購買了 50 股。對沖基金和其他機構投資者持有該公司 93.90% 的股票。</p>
<h2>西氏醫藥服務公司簡介</h2>
<p>（獲取免費報告）</p>
<p>西氏醫藥服務公司是一家全球開發和製造組件、系統和服務的公司，旨在實現可注射藥物的封裝和輸送。該公司專注於為製藥和生物技術行業提供高質量的包裝和輸送解決方案，生產用於疫苗、生物製劑和其他可注射療法的主要藥物包裝組件和專業藥物輸送設備。西氏以其彈性密封件、密封和聚合物組件而聞名，這些產品能夠保持無菌性並與敏感藥物配方兼容。</p>
<p>除了組件製造，西氏還提供工程化輸送系統和產品生命週期支持服務。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過西氏醫藥服務</li>
<li>準備好：3 個即將到來的催化劑可能推動 Oracle 創下新高</li>
<li>應對大型製藥專利懸崖的兩種方式</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先量子公司在第一季度財報後的比較</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

美國醫藥設備 ETF - iShares

生物科技 ETF - VanEck Vectors

<p>Zacks Research 將西氏醫藥服務（NYSE:WST）的評級從 “持有” 上調至 “強力買入”。其他分析師，包括 Evercore 和 UBS，也重申了積極的評級，目標價格範圍在 310 美元到 340 美元之間。該公司報告了強勁的季度收益，每股收益為 2.13 美元，營收為 8.449 億美元，均超出預期。西氏醫藥還啓動了一項 10 億美元的股票回購計劃，顯示出對其股票價值的信心</p>

<p>West Pharmaceutical Services (NYSE:WST - Get Free Report) was upgraded by equities researchers at Zacks Research from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST - 獲取免費報告）在週三發佈的研究報告中被 Zacks Research 的股票研究人員從 “持有” 評級上調至 “強力買入” 評級，Zacks.com 報道。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>Other analysts have also issued research reports about the stock. Evercore reaffirmed an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. UBS Group reaffirmed a &#34;buy&#34; rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;buy&#34; rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Citigroup reaffirmed a &#34;buy&#34; rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, Barclays lifted their price target on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the company an &#34;equal weight&#34; rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $322.89.</p>
<div class="lb-trans"><p>其他分析師也對該股票發佈了研究報告。Evercore 在 4 月 24 日的研究報告中重申了對西氏醫藥服務股票的 “跑贏大盤” 評級。瑞銀集團在 2 月 13 日的研究報告中重申了 “買入” 評級，並設定了 340.00 美元的目標價。德意志銀行在 2 月 13 日的研究報告中重申了 “買入” 評級，並設定了 315.00 美元的目標價。花旗集團在 4 月 24 日的研究報告中重申了對西氏醫藥服務的 “買入” 評級。最後，巴克萊在 4 月 27 日的研究報告中將西氏醫藥服務的目標價從 275.00 美元上調至 310.00 美元，並給予該公司 “持平” 評級。兩位研究分析師對該股票給予了強力買入評級，七位給予了買入評級，三位給予了持有評級。根據 MarketBeat.com 的數據，西氏醫藥服務目前的平均評級為 “適度買入”，共識目標價為 322.89 美元。</p>
</div><p><strong>Read Our Latest Report on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於西氏醫藥服務的最新報告</strong></p>
</div><h2>West Pharmaceutical Services Stock Down 0.7%</h2>
<div class="lb-trans"><h2>西氏醫藥服務股票下跌 0.7%</h2>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>什麼因素將推動標準普爾 500 指數今年的表現？</li>
</ul>
</div><p>WST stock opened at $300.13 on Wednesday. The firm has a market cap of $21.20 billion, a PE ratio of 40.12, a PEG ratio of 2.53 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The firm's 50 day moving average price is $267.64 and its 200-day moving average price is $265.17. West Pharmaceutical Services has a one year low of $202.79 and a one year high of $330.88.</p>
<div class="lb-trans"><p>WST 股票在週三開盤價為 300.13 美元。該公司的市值為 212 億美元，市盈率為 40.12，市盈增長比率為 2.53，貝塔值為 1.17。公司的債務與股本比率為 0.07，速動比率為 2.04，流動比率為 2.71。該公司的 50 日移動平均價格為 267.64 美元，200 日移動平均價格為 265.17 美元。西氏醫藥服務的年內最低價為 202.79 美元，年內最高價為 330.88 美元。</p>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services will post 8.61 EPS for the current year.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST - 獲取免費報告）在 4 月 23 日星期四發佈了季度財報。這家醫療器械供應商報告季度每股收益為 2.13 美元，超出市場共識預期的 1.68 美元，超出幅度為 0.45 美元。該公司季度收入為 8.449 億美元，而分析師預期為 7.7968 億美元。西氏醫藥服務的淨利潤率為 16.85%，股本回報率為 19.03%。該公司季度收入同比增長 21.0%。在去年同期，該公司每股收益為 1.45 美元。西氏醫藥服務已將其 2026 財年的指導目標設定為每股收益 8.400-8.750 美元，2026 年第二季度的指導目標設定為每股收益 2.050-2.120 美元。平均而言，股票研究分析師預計西氏醫藥服務今年將發佈每股收益 8.61 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>West Pharmaceutical Services announced that its Board of Directors has initiated a share repurchase plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.</p>
<div class="lb-trans"><p>西氏醫藥服務宣佈其董事會於 2 月 17 日啓動了一項股票回購計劃，允許公司回購 10 億美元的流通股。該回購授權允許這家醫療器械供應商通過公開市場購買最多 5.6% 的股份。股票回購計劃通常表明公司的領導層認為其股票被低估。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the business's stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company's stock, valued at $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, VP Annette F. Favorite sold 2,817 shares of the business's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他西氏醫藥服務的新聞中，首席會計官 Chad Winters 在 4 月 27 日星期一出售了 896 股公司的股票。股票以平均價格 300.67 美元出售，總價值為 269,400.32 美元。出售後，首席會計官持有 1,523 股公司的股票，價值為 457,920.41 美元。此次交易使其持股減少了 37.04%。該出售在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，副總裁 Annette F. Favorite 在 4 月 27 日星期一出售了 2,817 股公司的股票。股票以平均價格 305.20 美元出售，總價值為 859,748.40 美元。出售完成後，副總裁直接持有公司 16,828 股，價值約為 5,135,905.60 美元。此次交易使其持股減少了 14.34%。該出售的 SEC 文件提供了更多信息。0.60% 的股票由內部人士持有。</p>
</div><h2>Institutional Trading of West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>西氏醫藥服務的機構交易</h2>
</div><p>Large investors have recently modified their holdings of the stock. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $25,000. Bayban purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $27,000. Private Trust Co. NA increased its position in shares of West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 61 shares during the period. DV Equities LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $28,000. Finally, Cornerstone Planning Group LLC increased its position in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 50 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股票的持有。Elyxium Wealth LLC 在第四季度購買了西氏醫藥服務的新股份，價值 25,000 美元。Bayban 在第四季度購買了西氏醫藥服務的新股份，價值 27,000 美元。Private Trust Co. NA 在第四季度將其在西氏醫藥服務的持股增加了 156.4%。Private Trust Co. NA 現在擁有 100 股這家醫療器械供應商的股票，價值 28,000 美元，此前在此期間又購買了 61 股。DV Equities LLC 在第四季度購買了西氏醫藥服務的新股份，價值 28,000 美元。最後，Cornerstone Planning Group LLC 在第一季度將其在西氏醫藥服務的持股增加了 90.9%。Cornerstone Planning Group LLC 現在擁有 105 股這家醫療器械供應商的股票，價值 26,000 美元，此前在此期間又購買了 50 股。對沖基金和其他機構投資者持有該公司 93.90% 的股票。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏醫藥服務公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏醫藥服務公司是一家全球開發和製造組件、系統和服務的公司，旨在實現可注射藥物的封裝和輸送。該公司專注於為製藥和生物技術行業提供高質量的包裝和輸送解決方案，生產用於疫苗、生物製劑和其他可注射療法的主要藥物包裝組件和專業藥物輸送設備。西氏以其彈性密封件、密封和聚合物組件而聞名，這些產品能夠保持無菌性並與敏感藥物配方兼容。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了組件製造，西氏還提供工程化輸送系統和產品生命週期支持服務。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs</li>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過西氏醫藥服務</li>
<li>準備好：3 個即將到來的催化劑可能推動 Oracle 創下新高</li>
<li>應對大型製藥專利懸崖的兩種方式</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先量子公司在第一季度財報後的比較</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

West Pharmaceutical Services (NYSE:WST) Upgraded to "Strong-Buy" at Zacks Research

Market Beat

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

標普健康醫療設備 ETF - SPDR

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

Evercore

瑞銀集團

德意志銀行

花旗

巴克萊銀行

標普 500 指數

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

西氏醫藥服務（NYSE:WST）被 Zacks Research 升級為 “強力買入” 評級